These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22555971)

  • 1. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease.
    Rodriguez-Otero P; Porcher R; Peffault de Latour R; Contreras M; Bouhnik Y; Xhaard A; Andreoli A; Ribaud P; Kapel N; Janin A; Socié G; Robin M
    Blood; 2012 Jun; 119(24):5909-17. PubMed ID: 22555971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin and α1-antitrypsin dynamics in gastrointestinal GvHD.
    O'Meara A; Kapel N; Xhaard A; Sicre de Fontbrune F; Manéné D; Dhedin N; de Latour RP; Socié G; Robin M
    Bone Marrow Transplant; 2015 Aug; 50(8):1105-9. PubMed ID: 25961766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation.
    Lorenz F; Marklund S; Werner M; Palmqvist R; Wahlin BE; Wahlin A
    Sci Rep; 2015 Jan; 5():7920. PubMed ID: 25605402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease.
    Broglie L; Rademaker A; Galvin J; Ray A; Tse WT; Duerst R; Schneiderman J; Kletzel M; Chaudhury S
    Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):169-174. PubMed ID: 29397331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoscopic and Histological Findings Are Predicted by Fecal Calprotectin in Acute Intestinal Graft-Versus-Host-Disease.
    Adam B; Koldehoff M; Ditschkowski M; Gromke T; Hlinka M; Trenschel R; Kordeals L; Steckel NK; Beelen DW; Liebregts T
    Dig Dis Sci; 2016 Jul; 61(7):2019-26. PubMed ID: 26995779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation.
    Metafuni E; Giammarco S; De Ritis DG; Rossi M; De Michele T; Zuppi C; Bacigalupo AP; Sica S; Chiusolo P
    Ann Hematol; 2017 Jun; 96(6):929-933. PubMed ID: 28293713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Steroid-Refractory Gastrointestinal Graft-Versus-Host Disease Is Not Associated With Significant Differences in Gut Taxonomic Composition Compared to Steroid-Sensitive Gastrointestinal Graft-Versus-Host Disease Immediately Before Onset of Disease.
    Zeng K; Brewster R; Kang JB; Tkachenko E; Brooks E; Bhatt AS; Fodor AA; Andermann TM
    Transplant Cell Ther; 2024 Feb; 30(2):237.e1-237.e9. PubMed ID: 37944820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal Calprotectin, Elastase, and Alpha-1-Antitrypsin Levels After Roux-en-Y Gastric Bypass; Calprotectin Is Significantly Elevated in the Majority of Patients.
    Boerlage TC; Westerink F; Poland DC; Huibregtse IL; Acherman YI; Gerdes VE
    Obes Surg; 2016 Dec; 26(12):2974-2980. PubMed ID: 27216731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease.
    Legoff J; Resche-Rigon M; Bouquet J; Robin M; Naccache SN; Mercier-Delarue S; Federman S; Samayoa E; Rousseau C; Piron P; Kapel N; Simon F; Socié G; Chiu CY
    Nat Med; 2017 Sep; 23(9):1080-1085. PubMed ID: 28759053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease.
    Im JS; Abraham SC; Saliba RM; Rondon G; Ross WA; Rashid A; Shpall EJ; Popat U; Qazilbash MH; Hosing C; Oran B; Shah N; Tewari P; Nieto Y; Kebriaei P; Champlin RE; Alousi AM
    Am J Surg Pathol; 2017 Nov; 41(11):1483-1490. PubMed ID: 28834808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal calprotectin in allogeneic stem cell transplantation for the diagnosis of acute intestinal graft versus host disease.
    Bastos Oreiro M; Castilla-Llorente C; de la Guía AL; de Paz R; Van Domselaar M; Nieto J; Rodriguez A; Gallardo D; Canales M;
    Bone Marrow Transplant; 2012 Sep; 47(9):1241-2. PubMed ID: 22307017
    [No Abstract]   [Full Text] [Related]  

  • 12. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
    Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
    Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Utility of Endoscopy and Biopsy in Suspected Acute Gastrointestinal Graft-versus-Host Disease after Hematopoietic Progenitor Cell Transplantation.
    Scott AP; Tey SK; Butler J; Kennedy GA
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1294-1298. PubMed ID: 29410342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favourable survival in "Discordant" acute gastrointestinal graft versus host disease (GI-GVHD) is explained by mild clinical course and treatment-responsive disease.
    Scott AP; Thirunavukarasu C; Kennedy GA; Tey SK
    Int J Hematol; 2020 Apr; 111(4):574-578. PubMed ID: 31912373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of gastrointestinal graft-versus-host disease according to the treatment response.
    Tamaki M; Nakasone H; Misaki Y; Yoshimura K; Gomyo A; Hayakawa J; Kusuda M; Akahoshi Y; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
    Ann Hematol; 2018 Oct; 97(10):1951-1960. PubMed ID: 29860563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of Endoscopic Procedure in Children With Clinically Suspected Gastrointestinal Graft-versus-host Disease.
    Mårtensson T; Szakos A; Mellgren K; Toporski J; Arvidson J; Casswall TH; Gustafsson B
    J Pediatr Gastroenterol Nutr; 2018 May; 66(5):744-750. PubMed ID: 29045348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
    Ferrara JL; Harris AC; Greenson JK; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Huber E; Landfried K; Akashi K; Vander Lugt M; Reddy P; Chin A; Zhang Q; Hanash S; Paczesny S
    Blood; 2011 Dec; 118(25):6702-8. PubMed ID: 21979939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease.
    Schwiertz A; Spiegel J; Dillmann U; Grundmann D; Bürmann J; Faßbender K; Schäfer KH; Unger MM
    Parkinsonism Relat Disord; 2018 May; 50():104-107. PubMed ID: 29454662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation.
    Chiusolo P; Metafuni E; Giammarco S; Bellesi S; Piccirillo N; Fanali C; Castagnola M; Zuppi C; De Michele T; Leone G; Sica S
    Blood; 2012 Nov; 120(22):4443-4. PubMed ID: 23175663
    [No Abstract]   [Full Text] [Related]  

  • 20. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
    Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE
    Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.